Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.
News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.
Celyad Oncology (Euronext: CYAD) announced it received a transparency notification under Article 14 of the Belgian Transparency Law from Tolefi SA and related persons. The notification, dated July 24, 2026, indicates a passive crossing below the 10% shareholding threshold on July 16, 2026.
According to the company, Tolefi SA and related persons now jointly hold 6,568,978 shares, representing 8.77% of Celyad Oncology’s 74,883,166 voting rights. The holding is mainly via Tolefi SA (6,504,864 voting rights or 8.69%), with smaller positions held by Serge Goblet (56,180), Isabelle Thoumyre (7,300), Jérôme Goblet (250) and Jean-Daniel Goblet (384). No equivalent financial instruments are reported. Tolefi SA is controlled by Serge Goblet and Isabelle Thoumyre. The full notification and press release are available on Celyad Oncology’s website.
Celyad Oncology (Euronext: CYAD) reported an update of its share capital and voting rights following the issuance on 16 July 2026 of 2,500,000 new shares to an affiliate of Fortress Investment Group. After this capital increase, total share capital amounts to EUR 10,437,000.00, represented by 47,261,905 shares.
The company now has 19,640,644 shares with single voting rights and 27,621,261 shares with double voting rights, for a total of 74,883,166 voting rights. Attributed warrants total 3,487,923, leading to 50,749,828 diluted shares and 78,371,089 diluted shares with voting rights.
Celyad Oncology (Euronext: CYAD) entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group. Fortress will subscribe to 2,500,000 new shares at €0.20 per share, a 15% discount to the 10-day VWAP. The placement, executed under authorized capital with cancellation of existing shareholders’ preferential rights in favor of Fortress, is expected to close around 15 July 2026, subject to customary conditions.
Following issuance, Fortress is expected to hold about 60.52% of shares and 68.75% of voting rights. Net proceeds will fund working capital and general corporate purposes, and Celyad Oncology expects its cash runway to extend from Q3 2026 to mid Q2 2027.
Celyad Oncology (Euronext: CYAD) reported FY2025 results and a business update on April 2, 2026. Key points: the company sold its research facility for €3.0m (gain €2.3m), discontinued R&D, recorded operating profit of €0.9m and net profit of €0.8m. Treasury stood at €1.7m, sufficient into Q3 2026 but insufficient for the following 12 months; auditor flagged a material uncertainty on going concern. The board will propose continuation under Belgian law at the May 20, 2026 shareholders meeting.
Celyad Oncology (Euronext: CYAD) has sold the C-Cathez® transendocardial catheter and associated intellectual property to CellProthera.
The agreement transfers all IP and technical documentation for the catheter, provides up to €5 million in milestone-linked instalments plus future royalties on net sales, and is fully deferred so it will not affect Celyad Oncology’s cash runway, currently anticipated to extend into Q3-2026.
Celyad Oncology (Euronext: CYAD) received a transparency notification dated November 20, 2025, reporting that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has passively crossed above the 65% threshold.
As of the threshold crossing on November 14, 2025, CFIP CLYD (UK) Limited holds 49,050,641 voting rights, equal to 67.77% of the 72,383,166 voting rights denominator. This increase reflects double voting rights applied from 14 November 2025 to shares issued in the 14 November 2023 private placement, bringing CFIP's shares with double voting rights to 22,858,654.
The notification details the full ownership chain and states Fortress can exercise voting rights via its investment advisers without client instruction. The crossing is described as a passive upward movement above the 65% threshold.
Celyad Oncology (Euronext: CYAD) reported its updated share and voting-rights totals as of 14 November 2025.
- 14,903,846 shares of CFIP CLYD (UK) Limited now carry double voting rights.
- Total number of shares: 44,761,905.
- Total voting rights after the change: 72,383,166.
- Total share capital: €9,216,154.53.
- Attributed warrants: 3,856,134, producing a diluted share count of 48,618,039 and diluted voting rights of 76,239,300.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on disclosure of major participations.
Celyad Oncology (Euronext: CYAD) has announced the divestment of its research facility in Mont-Saint-Guibert, Belgium. The company will sell the facility's equipment and office furniture for €3 million.
The transaction, subject to customary conditions, is expected to close in Q4 2025. This strategic move is anticipated to extend the company's cash runway by approximately three quarters, reaching into Q3 2026.
Celyad Oncology (Euronext: CYAD) reported its financial results for H1 2025, showing a deteriorating financial position. The company's cash position dropped to €0.8 million as of June 30, 2025, compared to €4.2 million at the end of 2024. The net loss increased to €3.7 million (€0.09 per share) from €3.0 million (€0.07 per share) in H1 2024.
R&D expenses increased by €0.6 million to €2.1 million, primarily due to higher IP costs and catheter development expenses. G&A expenses remained stable at €1.7 million. The company projects its current cash position will only fund operations into Q4 2025, indicating potential liquidity concerns.
Celyad Oncology (CYAD) announced a significant change in its voting rights structure as CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has passively crossed below the 60% threshold. The company now holds 34,146,795 voting rights, representing 59.41% of Celyad Oncology's total voting rights.
The change resulted from the maturation of double voting rights on shares issued during the September 2023 private placement. CFIP CLYD (UK) Limited's 7,954,808 shares now carry double voting rights, but due to another shareholder's larger stake also receiving double voting rights, their overall percentage decreased.